Stockscreener 앱 받기
4.57
0.44%
-0.00
전일 마감가:
$4.57
열려 있는:
$4.53
하루 거래량:
106.18K
Relative Volume:
0.14
시가총액:
$316.55M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-4.1927
EPS:
-1.09
순현금흐름:
$-13.59M
1주 성능:
+26.74%
1개월 성능:
+76.36%
6개월 성능:
+258.27%
1년 성능:
+358.44%
1일 변동 폭
$4.4291
$4.62
1주일 범위
$3.529
$4.62
52주 변동 폭
$0.65
$4.62
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.59 | 315.17M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.44 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.48 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
733.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.97 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.69 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
FDA reviewing NC biotech's treatment for age-related vision loss - The Business Journals
Where Opus Genetics Stands With Analysts - Sahm
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - The Manila Times
Opus Genetics (NASDAQ:IRD) Price Target Raised to $12.00 - MarketBeat
FY2026 EPS Estimates for Opus Genetics Raised by Analyst - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics (NASDAQ:IRD) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Opus Genetics reports early positive data from gene therapy trial - Investing.com South Africa
Opus Genetics (IRD) Shares Promising Gene Therapy Results - GuruFocus
Opus Genetics reports early positive data from gene therapy trial By Investing.com - Investing.com Canada
Opus Genetics Announces Initial Clinical Data from Phase - GlobeNewswire
IRD Should I Buy - Intellectia AI
Opus Genetics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
FDA accepts Opus Genetics’ presbyopia treatment application By Investing.com - Investing.com Australia
FDA accepts sNDA of phentolamine 0.75% for presbyopia - Eyes On Eyecare
FDA accepts Opus Genetics’ presbyopia treatment application - Investing.com Nigeria
Viatris, Opus Genetics Say US FDA Agrees to Review New Drug Application for Potential Eye Condition Treatment - marketscreener.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Reviews Opus Genetics' (IRD) New Eye Treatment for Presbyopi - GuruFocus
Opus Genetics Announces FDA Acceptance Of Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia - TradingView
Eye drops for aging eyes: FDA reviews Opus presbyopia treatment - Stock Titan
Chipmakers Recap: Can Opus Genetics Inc weather a recessionProduct Launch & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 (NASDAQ:IRD) - Seeking Alpha
Aug Patterns: Can Ameresco Inc beat the S P 500Weekly Investment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Opus Genetics (NASDAQ:IRD) Cut to "Sell" at Wall Street Zen - MarketBeat
Opus Genetics (NASDAQ:IRD) Cut to “Sell” at Wall Street Zen - Defense World
Balyasny Asset Management L.P. Acquires Significant Stake in Opu - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Opus Genetics Inc - GuruFocus
Opus Genetics Closes $25 Million Series B Financing - TipRanks
Opus Genetics Raises $25 Million in Private Placement of Series B Preferred at $3.39 - TradingView
Opus Genetics (NASDAQ: IRD) boosts cash with $25M Series B preferred - Stock Titan
Aug Technicals: Can Fulgent Genetics Inc stock outperform in a bear marketQuarterly Investment Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
MSN Money - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Rating of "Buy" by Brokerages - MarketBeat
Opus Genetics Enters Agreement for $25 Million Private Placement - VisionMonday.com
Opus Genetics Insider Confidence Rewarded, Stock Hits US$233m Market Cap - 富途牛牛
Opus Genetics higher after $25M private placement - MSN
Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Fed Impact & Verified Stock Trade Ideas - mfd.ru
Lifesci Capital Forecasts Opus Genetics FY2025 Earnings - MarketBeat
Can Opus Genetics Inc. reach all time highs this yearWeekly Profit Summary & Weekly Return Optimization Plans - mfd.ru
Is Opus Genetics Inc. stock a good pick for beginnersJuly 2025 Chart Watch & Real-Time Volume Triggers - mfd.ru
Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Drops By 30.7% - MarketBeat
Aug Sentiment: Is FirstService Corporation stock risky to hold nowMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Opus Genetics raises $25 million in private placement financing By Investing.com - Investing.com Australia
Opus Genetics (NASDAQ:IRD) Raised to Strong-Buy at Lifesci Capital - Defense World
Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding - marketscreener.com
Opus Genetics raises $25 million in private placement financing - Investing.com India
Opus Genetics announces $25 million private placement - marketscreener.com
Opus Genetics Announces $25 Million Private Placement - TradingView
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opus Genetics Inc 주식 (IRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gallagher Cam | Director |
Dec 29 '25 |
Buy |
1.98 |
81,000 |
160,275 |
1,891,430 |
| Foundation Fighting Blindness | Director |
Dec 09 '25 |
Sale |
2.15 |
4,000,000 |
8,600,000 |
5,492,171 |
0.50%
자본화:
|
볼륨(24시간):